Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Prevalence of HIV-1 transmitted drug resistance and viral suppression among recently diagnosed adults in SAo Paulo, Brazil

Full text
Show less -
Ozorio Coelho, Luana Portes [1] ; Matsuda, Elaine Monteiro [2] ; Nogueira, Roberta Schiavon [3] ; de Moraes, Monica Jacques [4] ; Jamal, Leda Fatima [3] ; Ramalho Madruga, Jose Valdez [3] ; Tancredi, Mariza Vono [3] ; Queiroz de Leao, Aline Carralas [3] ; Romero Soldi, Giselle de Faria [1] ; de Macedo Brigido, Luis Fernando [1] ; Colpas, Daniela Rodrigues ; Cabral, Gabriela Bastos ; Lopes, Giselle Ibete Silva Lopez ; Campos, Norberto Camilo ; Ribeiro, Isadora Coutinho ; Ahagon, Cintia Mayumi ; Teixeira, Guilherme Penteado ; Ferreira, Joao Leandro de Paula ; de Campos, Ivana Barros ; Carvalho, Mariana ; Gomes, Rafaella ; Pinheiro, Flavia Gennari ; Pereira, Jr., Luiz Carlos ; Morejon, Karen ; da Costa, Alvaro Furtado ; Kalmar, Erika Maria do Nascimento ; Nogui, Fabio Luis Nascimento ; Mueller, Patricia Rady ; Goulart, Silvia Pereira ; Leme, Suzana Toledo da Silva ; Workgrp, MIHR
Total Authors: 31
[1] Adolfo Lutz Inst, Ctr Virol, Lab Retrovirus, Nucleo Doencas Sanguineas Sexuais, Av Dr Arnaldo 355, BR-01246902 Sao Paulo, SP - Brazil
[2] AIDS Santo Andre, Programa IST, SP, Santo Andre - Brazil
[3] AIDS, DST, CRT, Sao Paulo, SP - Brazil
[4] Univ Estadual Campinas, Fac Ciencias Med, Campinas, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: ARCHIVES OF VIROLOGY; v. 164, n. 3, p. 699-706, MAR 2019.
Web of Science Citations: 3

HIV-1 transmitted drug resistance (TDR) mutations may reduce the efficacy of antiretroviral therapy (ART), but pre-treatment testing to determine the virus genotype can improve the efficacy of ART. Unfortunately, issues related to cost and logistics of pre-treatment testing limit its use in resource-limited settings. We studied 596 ART-naive individuals who were newly diagnosed from 2014 to 2016 in SAo Paulo, Brazil, to evaluate TDR and virological outcome after 48weeks of genotype-guided therapy. One or more TDR (based on the WHO surveillance list) was observed in 10.9% (CI 95%, 8.6-13.6) of the sequences, the most common of which was the K103N mutation, which confers resistance to first-generation drugs of the non-nucleoside reverse transcriptase inhibitor (NNRTI) antiretroviral drug class. Dual-class (1%, 6/596) and triple-class (0.34%, 2/596) resistance were uncommon. After 48weeks of treatment with ART, infection was suppressed to below 200 copies/mL in most patients (95%), with full suppression (RNA target not detected) in 65%. The following characteristics at patient enrollment were independently associated with a lack of full suppression: CD4 T cell counts below 500 cells/mu L, viremia above 100,000 copies/mL, older age, and TDR to NNRTI. The rates of resistance were intermediate, but genotype-guided therapy resulted in high rates of viral suppression. The observed resistance profile should not be an obstacle to the use of the dolutegravir-based regimen now recommended in Brazil, but genotype testing may be warranted before initiating first-generation NNRTI-based regimens. (AU)

FAPESP's process: 16/14813-1 - Evaluation of molecular biology technology for plasma viremia detection to the identification and incorporation of patients at acute phase of HIV-1 infection
Grantee:Ivana Barros de Campos
Support Opportunities: Research Grants - Research in Public Policies for the National Health Care System (PP-SUS)
FAPESP's process: 13/19441-7 - Identification and analysis of incident HIV-1 infection
Grantee:Luís Fernando de Macedo Brígido
Support Opportunities: Regular Research Grants